Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 6 of 6 publications.
Skip to main content
Jacobson EU, Hicks KA, Carrico J, Purcell DW, Green TA, Mermin JH, Farnham PG. Optimizing HIV prevention efforts to achieve EHE incidence targets. J Acquir Immune Defic Syndr. 2022 Apr;89(4):373-80. doi: 10.1097/QAI.0000000000002885
Munro CE, Buckley R, Vannini P, DeMuro C, Sperling R, Rentz DM, Johnson K, Gathchel JR, Amariglio R. Longitudinal trajectories of participant- and study partner-rated cognitive decline, in relation to alzheimer's disease biomarkers and mood symptoms. Front Aging Neurosci. 2022 Jan 31;13:806432. doi: 10.3389/fnagi.2021.806432
Nance RM, Vannappagari V, Smith K, Johannes CB, Calingaert B, Saltus CW, Mayer KH, Whitney BM, Rodriguez B, Moore RD, Eron JJ, Geng E, Mathews WC, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC, Crane HM. Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings. J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):572-7. doi: 10.1097/QAI.0000000000002075
Minnis AM, Browne EN, Boeri M, Agot K, van der Straten A, Ahmed K, Weinrib R, Mansfield C. Young women's stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):394-403. doi: 10.1097/QAI.0000000000001945.
Chung AH, Leisner TM, Dardis GJ, Bivins MM, Keller AL, Parise LV. CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death. Cancer Cell Int. 2019 Feb 4;19(26). doi: 10.1186/s12935-019-0740-2
Khurana N, Yaylali E, Farnham PG, Hicks KA, Allaire BT, Jacobson E, Sansom SL. Impact of improved HIV care and treatment on PrEP effectiveness in the United States, 2016–2020. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):399-405. doi: 10.1097/QAI.0000000000001707